Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.44 |
| ▸ | WNT3A | P56704 | 3/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405144 | 0.86 | LMNA (0.58) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL6205138 | 0.85 | LMNA (0.47) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL6675290 | 0.83 | LMNA (0.51) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL7766866 | 0.82 | TSHR (0.59) | LMNATSHRL3MBTL1TDP1NPC1 | |
| SCHEMBL1994129 | 0.81 | TSHR (0.67) | LMNAGAAKCNK3KCNK9TSHR | |
| SCHEMBL28799431 | 0.80 | LMNA (0.49) | LMNAGAACTNNB1WNT3AL3MBTL1 | |
| SCHEMBL29410857 | 0.79 | CTNNB1 (0.57) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL1950901 | 0.79 | CTNNB1 (0.57) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL45490 | 0.79 | LMNA (0.59) | LMNAGAATSHR | |
| SCHEMBL31575818 | 0.79 | ALDH1A1 (0.69) | LMNAGAATSHRL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028407-A | A kind of method preparing -1 ', 3 '-dione compounds of spiral shell [cyclopropane -1,2 '-indenes] | 苏州大学 | 2019-07-19 | — | — | CN | disclosed |
| CN-106674174-B | A kind of 4,6- diaryl pyran derivate and its preparing the application in liver-cancer medicine | 辽宁大学 | 2019-02-19 | — | — | CN | disclosed |
| CN-106674174-A | 4, 6-diaryl pyran derivative and application thereof in preparation of liver cancer drugs | 辽宁大学 | 2017-05-17 | — | — | CN | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-2051977-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 | Amgen Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | LMNA 3047/4885GAA 1712/4885CTNNB1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.